Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: Results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1483-1488

  Sekine, I ^a   Ichinose, Y ^b   Nishiwaki, Y ^c   Yamamoto, N ^d   Tsuboi, M ^e   Nakagawa, K ^f   Shinkai, T ^g   Negoro, S ^h   Imamura, F ⁱ   Eguchi, K ^j   Takeda, K ^k   Itoh, Y ^l   Tamura, T ^a   Saijo, N ^c   Fukuoka, M ^f  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h HYOGO CANCER CENTER   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k OSAKA CITY GENERAL HOSPITAL   (Japan)

^l ASTRAZENECA   (United Kingdom)

more..

Author keywords

Docetaxel; Gefitinib; Non small cell lung cancer; Quality of life

Indexed keywords

DOCETAXEL; GEFITINIB;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

EID: 69849106072     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp031     Document Type: Article

References (14)

1. 2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001; 48: 356-360.
2. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
3. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
4. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-2158.
5. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
6. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26: 4244-4252.
7. Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
8. Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55: 285-295.
9. Osoba D, Bezjak A, Brundage M et al. Analysis and interpretation of health-related quality of life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280-287.
10. Cufer T, Vrdoljak E, Gaafar R et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006; 17: 401-409.
11. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183-194.
12. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
13. Kim ES, Hirsch V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: A randomised phase III trial (INTEREST). Lancet 2008; 372: 1809-1818.
14. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831-3837.